StockData
Agilent Technologies, Inc. logo

Agilent Technologies, Inc. (A) KPIs and segments

ANYSELaboratory Analytical InstrumentsFiscal year ends October 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 1, 2026Score 21/3019% above fair value
$172.22−0.70 (-0.40%)

Close on Nov 17, 2026Market cap $48.55BP/E 34.0Yield 0.58%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Agilent Technologies · năm tài chính kết thúc ngày 31 tháng 10

Nhìn nhanh KPI của Agilent Technologies: 43 chỉ số vận hành, trong đó có Core Revenue Growth, Life Sciences & Diagnostics Markets Group (LDG) và Agilent CrossLab Group (ACG), lấy từ 176 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Năm tài chính của Agilent Technologies kết thúc ngày 31 tháng 10 — Q3 FY26 = CQ2 2026 (quý dương lịch).

Periods

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 FY26
Q2 FY26
Q1 FY26
Q4 FY25
Q3 FY25
Q2 FY25
Q1 FY25
Q4 FY24
Q3 FY24
Q2 FY24
Q1 FY24
Q4 FY23
Agilent CrossLab($M)3
7867597587557447136967066916646861,492
Americas($M)
289289273290274270261269267259253536
Asia Pacific($M)
276248270248258249247247240223248564
Europe($M)
221222215217212194188190184182185392
Life Sciences and Diagnostics Markets($M)3
746732679755670654647657585604620
Americas($M)
369363307384316325312316268290283
Europe($M)
201214203218201177190186177176184
Asia Pacific($M)
176155169153153152145155140138153
Applied Markets($M)3
346344361351324301338338302305352
Asia Pacific($M)
161150163158152147157165140149169
Americas($M)
1031129810293839695918894
Europe($M)
82821009179718578716889
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2
Product($M)
1,3331,3051,2731,3281,2301,1861,2001,2171,1211,1251,2091,232
Non-Instrumentation and Other($M)
1,2351,2171,1401,2081,1391,1181,0561,0811,0221,0251,0281,037
Instrumentation($M)
643618658653599550625620556548630651
Services and Other($M)
545530525533508482481484457448449456
Americas($M)
761764678776683678669680626637630702
Asia Pacific($M)
613553602559563548549567520510570553
Europe($M)
504518518526492442463454432426458433
Agilent CrossLab($M)
270242240246248231221239248216222504
Life Sciences and Diagnostics Markets($M)
176161109172118129117141114115114
Applied Markets($M)
8680938771598486706492
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2
Agilent CrossLab($M)
448421418415410396390
Life Sciences and Diagnostics Markets($M)
414395343400338345342
Applied Markets($M)
198192204192174161188
Product($M)
774738702741653648665679630644695694
Services and Other($M)
268252244249235218234237225212213221
Life Sciences and Diagnostics Markets($M)
5,9975,9455,7905,866
Agilent CrossLab($M)
2,4272,4352,4212,360916925947897
Applied Markets($M)
882858873872
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2
Core Revenue Growth — Constant Currency, Excl. M&A (Headline Exact, % YoY)(%)9
7.3%6.3%4.4%7.2%6.1%5.3%1.2%-0.3%-4.4%-7.4%-6.4%-9.7%
Core Revenue Growth — Reconciliation Table Rounded (% YoY)(%)
7.0%6.0%4.0%7.0%6.0%5.0%1.0%-4.0%-7.0%-6.0%-10.0%
GAAP Reported Revenue Growth (Headline Exact, % YoY)(%)
8.1%10.0%7.0%9.4%10.1%6.0%1.4%0.8%-5.6%-8.4%-5.6%-8.7%
GAAP Reported Revenue Growth — Reconciliation Table Rounded (% YoY)(%)
8.0%10.0%7.0%9.0%10.0%6.0%1.0%1.0%-6.0%-8.0%-6.0%-9.0%
Non-GAAP Revenue Growth Excl. Acquisitions & Divestitures (% YoY)(%)
8.0%10.0%7.0%8.0%8.0%4.0%-5.0%-8.0%-5.0%-9.0%
Non-GAAP Core Revenue Excl. M&A ($M)($M)
1,8681,8351,7981,8391,7091,6311,6551,6911,5781,5731,6581,688
Currency (FX) Impact on Revenue Growth (percentage points)(%)
1.0%4.0%3.0%1.0%2.0%-1.0%-1.0%0.0%-1.0%-1.0%1.0%1.0%
Currency (FX) Impact on Revenue ($M)($M)
461441535-25-229-18-141620
Ignite Strategic Pricing Contribution to Revenue Growth (bps)(bps)
200200200150
Consecutive Quarters with Instrument Book-to-Bill Ratio ≥ 1.0 (quarters)
1098
Life Sciences & Diagnostics Markets Group (LDG) — Core Revenue Growth (% YoY)(%)5
10.0%9.0%3.0%11.0%7.0%3.0%1.0%
LDG — GAAP Revenue Growth (% YoY)(%)
11.0%12.0%5.0%15.0%14.0%8.0%4.0%
LDG — Non-GAAP Revenue Growth Excl. M&A (% YoY)(%)
10.0%12.0%5.0%12.0%9.0%2.0%
LDG — Non-GAAP Core Revenue Excl. M&A ($M)($M)
736732679733641617621
LDG — Currency (FX) Impact (percentage points)(%)
0.0%3.0%2.0%1.0%2.0%-1.0%-1.0%
LDG — Currency (FX) Impact ($M)($M)
12216613-7-6
Agilent CrossLab Group (ACG) — Core Revenue Growth (% YoY)(%)4
5.0%2.0%6.0%6.0%5.0%9.0%3.0%
ACG — GAAP Revenue Growth (% YoY)(%)
6.0%6.0%9.0%7.0%8.0%7.0%1.0%
ACG — Non-GAAP Revenue Growth Excl. M&A (% YoY)(%)
6.0%6.0%9.0%7.0%8.0%7.0%1.0%
ACG — Currency (FX) Impact (percentage points)(%)
1.0%4.0%3.0%1.0%3.0%-2.0%-2.0%
ACG — Currency (FX) Impact ($M)($M)
22920716-13-11
Applied Markets Group (AMG) — Core Revenue Growth (% YoY)(%)4
7.0%11.0%4.0%3.0%5.0%-2.0%
AMG — GAAP Revenue Growth (% YoY)(%)
7.0%14.0%7.0%4.0%7.0%-1.0%-4.0%
AMG — Non-GAAP Revenue Growth Excl. M&A (% YoY)(%)
7.0%14.0%7.0%4.0%7.0%-1.0%-4.0%
AMG — Currency (FX) Impact (percentage points)(%)
0.0%3.0%3.0%1.0%2.0%-1.0%-2.0%
AMG — Currency (FX) Impact ($M)($M)
110826-5-5
Legacy Life Sciences & Applied Markets Group (LSAG, pre-FY2025) — Core Revenue Growth (% YoY)(%)11
-1.0%-7.0%-13.0%-11.0%-18.0%
Legacy LSAG — GAAP Revenue Growth (% YoY)(%)
-1.0%-8.0%-14.0%-10.0%-17.0%
Legacy LSAG — Non-GAAP Core Revenue Excl. M&A ($M)($M)
833782754846928
Legacy LSAG — Currency (FX) Impact (percentage points)(%)
0.0%-1.0%-1.0%1.0%1.0%
Legacy Diagnostics & Genomics Group (DGG, pre-FY2025) — Core Revenue Growth (% YoY)(%)
-3.0%-8.0%-8.0%-6.0%
Legacy DGG — GAAP Revenue Growth (% YoY)(%)
-1.0%-9.0%-9.0%-6.0%1.0%
Legacy DGG — Non-GAAP Core Revenue Excl. M&A ($M)($M)
432385417407356
Legacy DGG — Currency (FX) Impact (percentage points)(%)
0.0%0.0%0.0%1.0%2.0%
Legacy Agilent CrossLab Group (ACG Pre-Recast, pre-FY2025) — Core Revenue Growth (% YoY)(%)
5.0%5.0%5.0%5.0%4.0%
Legacy ACG (Pre-Recast) — GAAP Revenue Growth (% YoY)(%)
5.0%4.0%4.0%6.0%6.0%
Legacy ACG (Pre-Recast) — Non-GAAP Core Revenue Excl. M&A ($M)($M)
426411402405404
Legacy ACG (Pre-Recast) — Currency (FX) Impact (percentage points)(%)
0.0%-1.0%-1.0%1.0%2.0%
Pharmaceutical & Biopharma End Market — Revenue ($M)($M)2
707663640690629603585595540542565590
Pharmaceutical & Biopharma End Market — Core Revenue Growth (% YoY)(%)
12.0%6.0%7.0%12.0%9.0%6.0%0.0%-1.0%-8.0%-11.0%-12.0%
Pharmaceutical & Biopharma End Market — Share of Consolidated Revenue (%)(%)
38.0%36.0%36.0%37.0%36.0%36.0%
Chemicals & Advanced Materials End Market — Revenue ($M)($M)2
430412422414399369379385356362392381
Chemicals & Advanced Materials End Market — Core Revenue Growth (% YoY)(%)
7.0%8.0%9.0%7.0%10.0%4.0%-2.0%1.0%-5.0%-3.0%-4.0%
Chemicals & Advanced Materials End Market — Share of Consolidated Revenue (%)(%)
23.0%23.0%23.0%22.0%23.0%22.0%
Diagnostics & Clinical End Market — Revenue ($M)($M)2
284295263276258255240255242239228236
Diagnostics & Clinical End Market — Core Revenue Growth (% YoY)(%)
6.0%11.0%7.0%7.0%4.0%8.0%7.0%7.0%2.0%-2.0%-5.0%
Diagnostics & Clinical End Market — Share of Consolidated Revenue (%)(%)
15.0%16.0%15.0%15.0%15.0%15.0%
Environmental & Forensics End Market — Revenue ($M)($M)2
171186177180163159172164168152166175
Environmental & Forensics End Market — Core Revenue Growth (% YoY)(%)
5.0%13.0%0.0%9.0%-5.0%6.0%6.0%-6.0%4.0%-2.0%-1.0%
Environmental & Forensics End Market — Share of Consolidated Revenue (%)(%)
9.0%10.0%10.0%10.0%9.0%10.0%
Food End Market — Revenue ($M)($M)2
158147166165157147168152144139157156
Food End Market — Core Revenue Growth (% YoY)(%)
0.0%-3.0%-4.0%7.0%7.0%8.0%9.0%-3.0%-3.0%-13.0%-3.0%
Food End Market — Share of Consolidated Revenue (%)(%)
8.0%8.0%9.0%9.0%9.0%9.0%
Academia & Government End Market — Revenue ($M)($M)2
128132130136132135137150128139150150
Academia & Government End Market — Core Revenue Growth (% YoY)(%)
-3.0%-5.0%-8.0%-10.0%1.0%-2.0%-7.0%-1.0%-11.0%-12.0%2.0%
Academia & Government End Market — Share of Consolidated Revenue (%)(%)
7.0%7.0%7.0%7.0%8.0%8.0%
Recurring Revenue: Consumables, Services & Informatics (Non-Instrumentation, $M)($M)2
1,2351,2171,1401,2081,1391,1181,0561,0811,0221,0251,0281,037
Recurring Revenue Share (Consumables, Services & Informatics, % of Total Revenue)(%)
66.0%66.0%63.0%65.0%66.0%67.0%
Instruments Revenue Share (% of Total Revenue)(%)
34.0%34.0%37.0%35.0%34.0%33.0%
Americas — Revenue ($M)($M)2
761764678776683678669680626637630702
Americas — Core Revenue Growth (% YoY)(%)
10.0%11.0%1.0%11.0%5.0%2.0%3.0%-6.0%-5.0%-8.0%
Americas — Share of Consolidated Revenue (%)(%)
40.0%42.0%38.0%42.0%39.0%41.0%
Europe — Revenue ($M)($M)2
504518518526492442463454432426458433
Europe — Core Revenue Growth (% YoY)(%)
2.0%8.0%4.0%11.0%7.0%6.0%2.0%0.0%-3.0%-4.0%
Europe — Share of Consolidated Revenue (%)(%)
27.0%28.0%29.0%28.0%28.0%26.0%
Asia-Pacific — Revenue ($M)($M)3
613553602559563548549567520510570553
Asia-Pacific (Total) — Core Revenue Growth (% YoY)(%)
9.0%-1.0%9.0%0.0%7.0%10.0%
Asia-Pacific — Share of Consolidated Revenue (%)(%)
33.0%30.0%33.0%30.0%33.0%33.0%
China — Core Revenue Growth (% YoY)(%)
9.0%-9.0%6.0%-4.0%4.0%10.0%2.0%-3.0%-11.0%-21.0%-9.0%
Life Sciences & Diagnostics Markets Group (LDG) — Segment Revenue ($M)($M)8
746732679755670654647657585604620674
Life Sciences & Diagnostics Markets Group (LDG) — Segment Gross Margin (%)(%)
55.5%54.1%50.5%52.9%50.5%52.8%52.8%53.8%54.4%55.1%54.9%55.8%
Life Sciences & Diagnostics Markets Group (LDG) — Segment Operating Margin (%)(%)
23.5%22.0%16.0%22.7%17.6%19.7%18.1%21.5%19.6%19.0%18.4%23.7%
Life Sciences & Diagnostics Markets Group (LDG) — Cost of Products and Services ($M, ASU 2023-07)($M)
332337336355332309305
Life Sciences & Diagnostics Markets Group (LDG) — Research & Development Expense ($M, ASU 2023-07)($M)
666465656159636159646665
Life Sciences & Diagnostics Markets Group (LDG) — Selling, General & Administrative Expense ($M, ASU 2023-07)($M)
172170169163159157162152145154160151
Life Sciences & Diagnostics Markets Group (LDG) — Share-Based Compensation Expense ($M)($M)
11111498915
Life Sciences & Diagnostics Markets Group (LDG) — Depreciation Expense ($M)($M)
24262625252423
Life Sciences & Diagnostics Markets Group (LDG) — Segment Goodwill Carrying Value ($M)($M)
3,5452,9972,9972,9962,9982,9992,9613,0002,489
Agilent CrossLab Group (ACG) — Segment Revenue ($M)($M)9
786759758755744713696706691664686672
Agilent CrossLab Group (ACG) — Segment Gross Margin (%)(%)
57.0%55.5%55.2%54.9%55.1%55.5%56.1%56.3%57.7%56.6%56.9%55.8%
Agilent CrossLab Group (ACG) — Segment Income from Operations ($M)($M)
270242240246248231221239248216222220
Agilent CrossLab Group (ACG) — Segment Operating Margin (%)(%)
34.3%32.0%31.6%32.5%33.3%32.4%31.8%33.8%35.9%32.5%32.4%32.8%
Agilent CrossLab Group (ACG) — Cost of Products and Services ($M, ASU 2023-07)($M)
338338340340334317306
Agilent CrossLab Group (ACG) — Research & Development Expense ($M, ASU 2023-07)($M)
282828272627262525262926
Agilent CrossLab Group (ACG) — Selling, General & Administrative Expense ($M, ASU 2023-07)($M)
150151150142136138143133126134139129
Agilent CrossLab Group (ACG) — Share-Based Compensation Expense ($M)($M)
1212161091116
Agilent CrossLab Group (ACG) — Depreciation Expense ($M)($M)
14141414141414
Agilent CrossLab Group (ACG) — Segment Goodwill Carrying Value ($M)($M)
1,1711,1721,1711,1681,1681,1671,1641,1681,166
Applied Markets Group (AMG) — Segment Revenue ($M)($M)8
346344361351324301338338302305352342
Applied Markets Group (AMG) — Segment Gross Margin (%)(%)
57.3%55.8%56.5%54.6%53.6%53.5%55.8%55.0%55.2%54.2%56.4%55.7%
Applied Markets Group (AMG) — Segment Operating Margin (%)(%)
24.9%23.3%25.8%24.7%21.8%19.5%25.0%25.3%23.2%21.0%26.1%25.9%
Applied Markets Group (AMG) — Cost of Products and Services ($M, ASU 2023-07)($M)
148152157159150140150
Applied Markets Group (AMG) — Research & Development Expense ($M, ASU 2023-07)($M)
242424242323232323232525
Applied Markets Group (AMG) — Selling, General & Administrative Expense ($M, ASU 2023-07)($M)
888887818079817774788277
Applied Markets Group (AMG) — Share-Based Compensation Expense ($M)($M)
5674458
Applied Markets Group (AMG) — Depreciation Expense ($M)($M)
6767666
Applied Markets Group (AMG) — Segment Goodwill Carrying Value ($M)($M)
314315316309309308304309305
Total Reportable Segments Income from Operations ($M)($M)3
532483442505437419422466432395428
Unallocated Corporate Expense: Amortization of Intangible Assets ($M)($M)
211919232627282525262627
Unallocated Corporate Expense: Acquisition & Integration Costs ($M)($M)
7123433974124
Unallocated Corporate Expense: Transformational Initiatives & Other ($M)($M)
86286139215252-9
Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — Segment Revenue ($M)($M)2
833782754846839
Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — Segment Gross Margin (%)(%)
59.1%60.2%59.4%60.2%59.5%
Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — Segment Operating Margin (%)(%)
28.0%28.4%24.7%27.9%28.6%
Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — Segment Revenue ($M)($M)2
442385417407445
Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — Segment Gross Margin (%)(%)
51.5%51.8%53.7%52.8%53.7%
Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — Segment Operating Margin (%)(%)
21.2%18.3%20.5%17.3%22.7%
Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Segment Revenue ($M)($M)6
426411402405404
Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Segment Gross Margin (%)(%)
50.9%52.1%50.2%50.5%50.4%
Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Segment Income from Operations ($M)($M)
139140123122128
Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Segment Operating Margin (%)(%)
32.6%34.0%30.5%30.2%31.7%
Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Americas Revenue ($M, 2D Segment × Region)($M)
173170167164167
Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Europe Revenue ($M, 2D Segment × Region)($M)
117113111111108
Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Asia-Pacific Revenue ($M, 2D Segment × Region)($M)
136128124130129
Remaining Performance Obligations (RPO on Contracts > 1 Year, $M)($M)6
434433459437425429408409344340344331
Total Contract Liabilities (Current & Long-Term Deferred Revenue, $M)($M)
822855877803800810782701646654644616
Current Deferred Revenue (Short-Term Contract Liabilities, $M)($M)
640665682624620628612544524533522505
Contract Liabilities Rollforward: Net Revenue Deferred in the Period ($M)($M)
671303015874120312136313925450
Contract Liabilities Rollforward: Revenue Recognized from Beginning Balance ($M)($M)
1011362504782117230267212122941
Contract Liabilities Rollforward: Change in Deferrals from Customer Cash Advances ($M)($M)
8-1110-6-3214-1-2-1-5-4
Contract Assets (Unbilled Accounts Receivable, $M)($M)
316326286329294289248247244242239252
Non-GAAP Net Income ($M)($M)11
459423386452390373377418385356380404
Non-GAAP Diluted EPS ($)($)
1.621.491.361.591.371.311.311.461.321.221.291.38
Non-GAAP Gross Margin (%)(%)
56.4%55.0%53.7%54.1%53.1%54.1%54.7%55.1%56.0%55.6%56.0%
Non-GAAP Operating Margin (%)(%)
28.3%26.4%24.6%27.2%25.1%25.1%25.1%27.4%27.4%25.1%25.8%
Non-GAAP Effective Tax Rate (%)(%)
14.5%14.5%14.5%12.0%12.0%11.5%12.5%11.2%13.0%12.5%13.5%13.8%
Net Leverage Ratio (Net Debt / Adjusted EBITDA, x)(×)
1.000.700.800.800.901.001.001.100.60
Non-GAAP Adjustment: Amortization of Intangible Assets ($M)($M)
211919232627282525262627
Non-GAAP Adjustment: Transformational Initiatives ($M)($M)
37391921182466113-6
Non-GAAP Adjustment: Restructuring & Workplace Optimization ($M)($M)
158208175615671346
Non-GAAP Adjustment: Acquisition & Integration Costs ($M)($M)
7123433974-124
Non-GAAP Adjustment: Other Non-GAAP Costs ($M)($M)
8727512961337-6-11
Non-GAAP Adjustment: Tax Effect of Non-GAAP Adjustments ($M)($M)
4-2-7-55-23-3-5-3415-4-119
Total Inventories, Net ($M)($M)3
1,1171,0891,0591,0251,0149919979729781,0001,0331,031
Finished Goods Inventory ($M)($M)
581561546547544529532523538551569570
Purchased Parts, Raw Materials & Work-in-Process Inventory ($M)($M)
536528513478470462465449440449464461
Inventory Charges for Excess & Obsolete Inventory ($M)($M)
10151015812101210121113
Total Gross Amortizable Intangible Assets ($M)($M)5
906407426445469495514547392417443475
Developed Technology — Gross Carrying Amount ($M)($M)
364229239249263279296315325342360374
Customer Relationships — Gross Carrying Amount ($M)($M)
51214915416016717417318428313437
Third-Party Technology & Licenses — Gross Carrying Amount ($M)($M)
8810111213141416181921
Trademarks & Trade Names — Gross Carrying Amount ($M)($M)
161516182021232523263033
Order & Production Backlog — Gross Carrying Amount ($M)($M)
66777889
FDA 510(k) Premarket Clearances — Agilent Technologies & Dako (clearances)3
000000000000
FDA Premarket Approvals (PMA & Supplements) — Agilent Technologies & Dako (approvals)
131234020010
FDA 510(k) Premarket Clearances — U.S. Medical Device Industry Total (clearances)
889835736823882767812814793750780941
FDA Premarket Approvals (PMA & Supplements) — U.S. Medical Device Industry Total (approvals)
616641434613597564607569575486582600
FDA MAUDE Adverse Event Reports — Agilent Technologies & Dako Total (reports)6
3136102726191922258
FDA MAUDE Device Malfunction Reports — Agilent Technologies & Dako (reports)
2136102726181922258
FDA MAUDE Injury Reports — Agilent Technologies & Dako (reports)
100000010000
FDA MAUDE Death Reports — Agilent Technologies & Dako (reports)
000000000000
FDA Medical Device Recalls — Agilent Technologies & Dako (recalls)
000301001000
FDA Device Enforcement Actions — Agilent Technologies & Dako (actions)
000301001000
FDA MAUDE Adverse Event Reports — U.S. Medical Device Industry Total (reports)
963,661824,539784,473760,623743,346650,998704,375705,389660,962598,054575,423611,520
BLS Producer Price Index: Analytical Laboratory Instrument Manufacturing (NAICS 334516, Index)(×)5
203.60203.60202.00196.10195.80195.20195.30191.60191.70191.60188.80186.80
BLS Producer Price Index: In-Vitro Diagnostic Substance Manufacturing (NAICS 325413, Index)(×)
300.60303.80305.00300.30298.20297.10292.20284.50284.50284.70286.10281.00
BLS Producer Price Index: Pharmaceutical Preparation Manufacturing (NAICS 325412, Index)(×)
928.80926.50924.20918.60915.20916.00913.60917.90915.40914.70905.90896.20
BLS Producer Price Index: Electromedical & Electrotherapeutic Apparatus (NAICS 334510, Index)(×)
92.8092.0091.9091.6090.3090.1090.0089.5089.2088.4088.0087.80
BLS Producer Price Index: Surgical & Medical Instrument Manufacturing (NAICS 339112, Index)(×)
163.20161.90161.70159.50157.00156.50157.20155.30154.50153.80153.30150.80
U.S. Census QSS: General Medical & Surgical Hospitals Revenue ($M)($M)
47,89646,67446,83446,29545,37045,35845,28443,77843,50543,70943,264
Consolidated Net Revenue ($M)($M)14
1,8781,8351,7981,8611,7381,6681,6811,7011,5781,5731,6581,688
Consolidated Cost of Products and Services ($M)($M)
836845852871850802782785723717750773
Consolidated Research & Development Expense ($M)($M)
123126117119111112113111127113128114
Consolidated Selling, General & Administrative Expense ($M)($M)
475465476428417454410397395380396393
Total Costs and Expenses ($M)($M)
1,4341,4361,4451,4181,3781,3681,3051,2931,2451,2101,2741,280
Consolidated Income from Operations ($M)($M)
444399353443360300376408333363384408
Interest Income ($M)($M)
151315171614152419191817
Interest Expense ($M)($M)
292525272829283222202222
Other Income (Expense), Net ($M)($M)
142121918-254113122317
Income Before Taxes ($M)($M)
444408364442366260367401343374403420
Provision for Income Taxes ($M)($M)
826959830454950616655-55
GAAP Net Income ($M)($M)
362339305434336215318351282308348475
GAAP Basic EPS ($)($)
1.281.201.081.180.751.120.971.051.19
GAAP Diluted EPS ($)($)
1.281.201.071.180.751.110.971.051.18
Cash Dividends Declared per Share ($)($)
0.260.260.260.250.250.250.250.240.240.240.240.23
Consolidated Total Assets ($M)($M)12
13,96713,06512,81312,72712,22612,15811,91411,84610,99610,85610,94810,763
Cash and Cash Equivalents ($M)($M)
1,7581,8071,7581,7891,5371,4891,4701,3321,7821,6741,7501,590
Accounts Receivable, Net ($M)($M)
1,4781,4981,5211,4871,3821,3661,3281,3241,2271,2491,2951,291
Inventories, Net ($M)($M)
1,1171,0891,0591,0251,0149919979729781,0001,0331,031
Property, Plant and Equipment, Net ($M)($M)
2,1342,0992,0782,0231,9661,9121,8161,7781,4461,3711,3141,270
Goodwill ($M)($M)
5,0304,4844,4844,4734,4754,4744,4294,4773,9653,9633,9673,960
Other Intangible Assets, Net ($M)($M)
906407426445469495514547392417443475
Operating Lease Right-of-Use Assets ($M)($M)
187181189183179182172177178162155154
Short-Term Debt & Current Portion of Long-Term Debt ($M)($M)
3043043043045914616457954200
Operating Lease Liabilities ($M)($M)
199187196189185189177184184170164164
Consolidated Total Liabilities ($M)($M)
6,6045,9435,9055,9865,8566,0225,8875,9485,0934,6424,7604,918
Total Stockholders' Equity ($M)($M)
7,3637,1226,9086,7416,3706,1366,0275,8985,9036,2146,1885,845
Common Shares Outstanding (Millions)(M)
282282283283284284285285288292293292
Operating Cash Flow ($M)($M)5
519277268545362221431481452333485516
Capital Expenditures ($M)($M)
807693931031149793921039084
Depreciation and Amortization ($M)($M)
666767717273726963636262
Cash Dividends Paid ($M)($M)
727272707170716868696966
Common Stock Repurchases ($M)($M)
7865152858516590335585230080
Acquisitions, Net of Cash Acquired ($M)($M)
95000000-48593000

5 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Core Revenue Growth (Group 1) is Agilent's primary operational performance indicator, measuring constant-currency revenue growth excluding acquisitions and divestitures within the first 12 months post-closing.
  • Effective Q1 FY2025 (three months ended January 31, 2025), Agilent reorganized its operating segments from LSAG, DGG, and ACG into Life Sciences & Diagnostics Markets Group (LDG), Agilent CrossLab Group (ACG), and Applied Markets Group (AMG). Recast quarterly and annual segment figures for FY2022–FY2024 are sourced from Form 8-K filed December 13, 2024, while legacy segment series through Q4 FY2024 are preserved in dedicated legacy rows.
  • Allowed period derivations: Fourth-quarter flow figures not separately tabulated in 10-K filings (such as Note 4 End-Market revenue, Product-Type revenue, 2D Segment × Geography revenue, and Note 22 ASU 2023-07 segment expenses) are derived as Q4 = Full Year (10-K) − Nine Months (10-Q) from matching reporting bases. Quarterly cash flow statement figures for Q2–Q4 are derived from cumulative year-to-date filings (6M − Q1, 9M − 6M, FY − 9M).
  • Consolidated minus standalone parent-only disaggregation does not apply because Agilent reports solely on a consolidated basis under U.S. GAAP and does not publish standalone parent-company financial statements.

Không hiện vì thiếu các kỳ gần đây (12)

  • Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — Segment Revenue ($M) › Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — R&D Expense ($M)
  • Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — Segment Revenue ($M) › Legacy Life Sciences & Applied Markets Group (LSAG, FY2019–FY2024) — SG&A Expense ($M)
  • Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — Segment Revenue ($M) › Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — R&D Expense ($M)
  • Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — Segment Revenue ($M) › Legacy Diagnostics & Genomics Group (DGG, FY2019–FY2024) — SG&A Expense ($M)
  • Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Segment Revenue ($M) › Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — R&D Expense ($M)
  • Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — Segment Revenue ($M) › Legacy Agilent CrossLab Group (Pre-Recast ACG, FY2019–FY2024) — SG&A Expense ($M)
  • Non-GAAP Net Income ($M) › Non-GAAP Adjustment: Asset Impairments ($M)
  • Non-GAAP Net Income ($M) › Non-GAAP Adjustment: (Gain) Loss on Equity Securities ($M)
  • Consolidated Total Assets ($M) › Long-Term Debt ($M)
  • Legacy Chemical Analysis Segment Revenue (discontinued after FY2014, $M)
  • Legacy Electronic Measurement / Keysight Segment Revenue (spun off in FY2015, $M)
  • Legacy Life Sciences Segment Revenue (reorganized in FY2015, $M)

Dữ liệu cập nhật 2026-11-08.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

5. Remaining Performance Obligations (RPO) & Contract Balances Rollforward

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Agilent Technologies

See a number that looks wrong?